New triple combo aims to hold back advanced breast cancer
NCT ID NCT07470203
First seen Mar 27, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This study looks at whether adding pyrotinib to two standard drugs (trastuzumab and pertuzumab) can help keep HER2-positive advanced breast cancer from growing longer. About 42 adults with advanced or recurrent HER2-positive breast cancer will receive this combination as maintenance therapy after initial treatment. The main goal is to see how long people stay free of disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.